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Background: In view of the prominent role in cancer cell biology and alteration in substantial numbers of ESCC,
defining EGFR molecular characteristics relevant to patient prognosis is of great importance. Therefore, we analyzed
the protein expression and gene copy variation of the epithelial growth factor receptor (EGFR) in Chinese
esophageal squamous cell carcinoma (ESCC) and explored the possible associations with various features of the
tumors and survival of the patients.
Methods: Sections were made from tissue microarray composed of 96 ESCC, and examined for EGFR expression by
means of immunohistochemistry (IHC) and for EGFR gene amplification by means of fluorescence in situ
hybridization (FISH). The results of IHC were evaluated with six different reported scoring systems. Correlation with
clinical features and survival was evaluated using chi-square test and Kaplan–Meier analysis.
Results: EGFR overexpression according to scoring system 1 significantly correlated with advanced lymph node
involvement (P = 0.046), patient disease specific free survival (DFS) (P = 0.006) and overall survival (OS) (P = 0.007). No
such association was observed using other 5 scoring systems (P > 0.05 ). EGFR amplification was associated with
lymph node metastasis (P = 0.028), but not correlated with DFS and OS until 20 months.
Conclusions: EGFR IHC overexpression evaluated by scoring system 1 might be suitable to be used in predicting
patients survival in ESCC. EGFR gene amplification showed delayed prognostic information after 20 months.
Keywords: Esophageal squamous cell carcinoma, Epidermal growth factor receptor, Immunohistochemistry scoring
system, Fluorescence in situ hybridizationBackground
Esophageal carcinoma is one of the most common ma-
lignancies in China, and squamous cell carcinoma is the
main histological type [1, 2]. It generally has a poor
prognosis because it is usually in an advanced stage at
the time of diagnosis. Despite the progress in chemo-
therapeutic, radiotherapeutic and surgical treatment, the
five-year survival rate is still less than 20 % [3-6]. In re-
cent years, molecular targeted therapy has become an
important treatment [7-10]. With the aim of increasing* Correspondence: houyingyong@hotmail.com; tan.lijie@zs-hospital.sh.cn
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unless otherwise stated.the clinical benefit–risk ratio of anticancer treatments,
consideration is increasingly given to the identification
of predictive tumour biomarkers.
One potential group of useful protein biomarkers is
the epidermal growth factor receptor (EGFR) family of
receptors. This family contains four members, EGFR,
ErbB2/human epidermal growth factor receptor-2
(HER2), ErbB3/HER3, and ErbB4/HER4, that act as re-
ceptor tyrosine kinases and have a well-defined function
in cell signaling, controlling cell proliferation and differ-
entiation. Esophageal cancers frequently show EGFR or
HER2 gene amplification and overexpression [11, 12].
And esophageal squamous cell carcinomas (ESCCs) pre-
dominantly show alterations of EGFR, whereas esopha-
geal (Barrett’s) adenocarcinomas (EACs) frequently showhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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view of the prominent role in cancer cell biology and
(over-)expression in substantial numbers of ESCC, EGFR
represents valuable therapeutic target. Defining EGFR mo-
lecular characteristics relevant to patient prognosis is an
important step toward deciding treatment.
At present, the literatures about EGFR expression in
ESCC contain conflicting data on the relationship between
overexpression and survival [13-15]. This variability may
be due to heterogeneity of study populations or lack of a
standardized assay for determining EGFR status. Here, we
collected a cohort of Chinese patients with ESCC, and
evaluated their protein expression using 6 representative
scoring systems. To the best of our knowledge and avail-
able literature data, so far such comparisons of different
EGFR-IHC scoring systems in ESCC patients are sparse.
EGFR gene copy number variation may be more reli-
able than protein expression in predicting prognosis.
However, reports on the influence of EGFR gene vari-
ation in ESCC patients have been equivocal [13, 16-18].
In general, the relationships between tumor EGFR gene
variation and protein expression have not been clearly
defined, and the prognostic value of these tumor charac-
teristics has not been well evaluated for ESCC.
Therefore, the aims of this study are to compare the
six different scoring systems for EGFR expression, to ex-
plore the cut off value in assessing EGFR gene variation,
and to investigate their prognostic significance in ESCC.
Methods
Patients and specimens
A total of 96 ESCC samples were treated in the Department
of Thorax Surgery, Zhongshan Hospital during March to
October 2010. All patients had not received chemotherapy
or radiotherapy prior to surgical resection. Prior writ-
ten informed consent was obtained from all patients.
The present study has been carried out in accordance
with the Declaration of Helsinki, and was approved by
Human Research Ethics Committee of Zhongshan hospital,
Fudan University.Table 1 Comparison of EGFR-IHC results of 6 scoring systems
Pairs Levels
System 1 vs. System 6 (L/M/H) vs. (L/M/H)
System 2 vs. System 3 (L/H) vs. (L/H)
System 2 vs. System 4 (L/H) vs. (L/H)
System 2 vs. System 5 (L/H) vs. (L/H)
System 3 vs. System 4 (L/H) vs. (L/H)
System 3 vs. System 5 (L/H) vs. (L/H)
System 4 vs. System 5 (L/H) vs. (L/H)
The McNemar Test, P < 0.05 was considered statistically significant difference
Kappa > =0.75 was regarded as better concordance, Kappa < 0.4 indicated a poor co
System 1–6, EGFR-IHC scoring system 1 to 6
L, low level of EGFR expression; M, intermediate level; H, high levelSections were stained with hematoxylin and eosin and
reviewed by two pathologists to confirm the ESCC diagno-
sis. The following patient characteristics were collected:
gender, age, tumor site (upper, middle, and lower region of
esophagus), histological grade, coagulative necrosis, nerve
and vascular infiltration, mitotic index (numbers recorded
as ≤20 per 10 high power fields [HPF], 20-50/10HPF, or ≥
50/10HPF), lymph node metastasis, and stage, as previ-
ously reported [19].
Tissue microarrays
The tissue microarray (TMA) was constructed as previ-
ously described [20]. Briefly, the region of interest (2 mm
wide and 6 mm long) was extracted and then vertically
planted into the recipient block one by one according to
the corresponding location indicated by letters and num-
bers. The planting surface was aggregated on the aggrega-
tion instrument.
Immunohistochemistry
The TMA recipient block was sectioned on a routine
microtome machine. The IHC assay using EGFR
rabbit monoclonal antibody (EGFR.25, Leica Biosystems
Newcastle Ltd, Newcastle, UK) was performed with the
Ventana iView DAB Detection Kit on a BenchMark XT
automated staining system (Ventana Medical Systems,
Tucson, AZ). Normal IgG from the same species of pri-
mary antibody diluted to match the concentration of the
primary antibody was used as the negative control. For
EGFR negative cases, the experiment was repeated on the
whole section in order to exclude heterogeneity.
EGFR expression was evaluated according to published
scoring system, summarized as follows:1) The percentage
of positive tumor cells (0 % to 100 %) was multiplied by the
staining intensity (SI) (1, negative or trace; 2, weak; 3,
moderate; 4, intense). Scores 0 to 200, 201 to 300, and 301
to 400 were respectively classified as having negative or
low, intermediate, and high levels of expression [21]. 2) 0,
negative, no discernible staining or background type stain-
ing; 1+, definite cytoplasmic staining and/or equivocalNumber P Kappa
(49/39/8) vs. (14/33/49) 0.001 0.037
(42/54) vs. (48/48) 0.031 0.875
(42/54) vs. (88/8) 0.001 0.132
(42/54) vs. (12/84) 0.001 0.31
(48/48) vs. (88/8) 0.001 0.167
(48/48) vs. (12/84) 0.001 0.25
(88/8) vs. (12/84) 0.001 0.026
ncordance
Fig. 1 Examples of different immunohistochemical EGFR expression in ESCC according to system 1: a = negative control, b = low, c = intermediate,
d = high level of EGFR expression
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membrane staining with moderate intensity; 3+, strong
and complete plasma membrane staining. Samples exhi-
biting 2+ or 3+ were classified as overexpression [13]. 3)
a = 0 % (score 0); 1–20 % (score 1); 21–40 % (score 2);
41–60 % (score 3); 61– 80 % (score 4); or 81–100 %
(score 5). i = absent (score 0); faint (score 1); moderate
(score 2); or strong (score 3). A final score was calculatedFig. 2 The representative EGFR (red) and chromosome 7 (green) FISH for t
polysomy (c, n = 22/96), Low polysomy ( d, n = 39/96), high trisomy (e, n =by multiplying i by a, using the score of 8 as the cutoff
[22]. 4) 1 × (percentage of cells staining weakly [1 +]) +
2 × (percentage of cells staining moderately [2 +]) +
3 × (percentage of cells staining strongly [3 +]). Score of 200
is a cutoff [23]. 5) SI was classified as 0 (negative), 1 (weak),
2 (moderate), and 3 (strong). An area of SI was defined
as 0 if <10 %, 1 if 10 %–25 %, 2 if 26 %–50 %, 3 if
51 %–75 %, and 4 if >75%. Immunostaining intensityumors with EGFR gene amplification (a and b, n = 7/96), High
6/96) and disomy (f, n = 3/96)
Table 2 Correlation between EGFR protein expression and gene
variation
EGFR-FISH result
EGFR-IHC FISH positive Amplification
No Yes P No Yes P
System 1 0.034 0.001
L 39 10 9 0
M 25 14 37 2
H 3 5 3 5
System 2 0.036 0.015
L 34 8 42 0
H 31 21 47 7
System 3 0.120 0.006
L 37 11 48 0
H 30 18 41 7
System 4 0.038 0.001
L 64 24 86 2
H 3 5 3 5
System 5 0.674 0.299
L 9 3 12 0
H 58 26 77 7
System 6 0.175 0.027
L 11 3 14 0
M 26 7 33 0
H 30 19 42 7
Total 67 29 89 7
System 1–6, EGFR-IHC scoring system 1–6
L, low level of EGFR expression; M, intermediate level; H, high level
FISH positive, EGFR gene amplification or high polysomy
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4–5 moderately positive (2+), and 6–7 strong positive
(3+); EGFR overexpression was defined as positive
staining of tumor cells reaching 2+ or 3 + [24]. 6) loss
of expression: SI = 0; weak expression: SI = 1 in < 70 %
or SI = 2 in < 30 % of cells in a tumor spot, moderate
expression: SI = 1 in > 70 % or SI =2 in > 30 % of cells in
a tumor spot and strong expression: SI = 2 in > 70 % or
SI = 3 in > 30 % of cells in a tumor spot [25].
Fluorescence in situ hybridization
TMA sections were dewaxed and dehydrated. Dual color
EGFR FISH was performed with the Spectrum Orange
locus-specific identifier EGFR probe (Vysis, Abbott Mo-
lecular Inc, Des plaines, USA) specific for the EGFR
locus (7p12) and the Spectrum Green CEP7 chromo-
some 7 centromeric probe (7p11.1 to q11.1; Vysis). The
specific steps were similar to HER2-FISH procedure, re-
ported previously [26].
EGFR signals were counted from at least 100 cancer cell
nuclei, and were divided into six types: 1) disomy was an
EGFR to CEP7 ratio ≤2 copies in >90 % of cells; 2)
low trisomy was ≤2 copies in ≥40 % of cells, 3 copies
in 10 %–40 % of the cells, ≥4 copies in <10 % of
cells; 3) high trisomy was ≤2 copies in ≥40 % of cells,
3 copies in >40 % of cells, ≥4 copies in <10 % of
cells; 4) low polysomy was ≥4 copies in 10 %–40 %
of cells; 5) high polysomy was ≥4 copies in >40 % of cells;
6) gene amplification was defined by the presence of tight
EGFR gene clusters, or a ratio of EGFR gene to chromo-
some7 ≥ 2, or ≥15 copies of EGFR per cell in ≥10 % of
tumor cells. EGFR FISH-positive was defined as EGFR
high polysomy or gene amplification [27].
Follow-up information
Follow-up information for the 96 patients after surgery
and treatment was provided by the referring clinicians,
or else obtained directly from patients and their family
members as standard procedure. The date of last follow
up was May 16, 2014. Disease-free survival (DFS) and
overall survival (OS) were measured from the time of
surgery to the time of first recurrence (or most recent
follow-up) or death.
Statistical analysis
A χ2 test was used for univariate analysis, the agreement
of different scoring systems was measured by the index
Kappa and the statistical differences were analyzed by
the McNemar test. Kaplan-Meier analysis was used to
calculate DFS and OS. Log-rank test of survival analysis
was used to compare DFS and OS as functions of vari-
ables and to identify significant differences. P < 0.05
were recorded as significant.Results
Characterization of ESCC patients
The clinicopathological features of the 96 ESCC patients
are summarized previously [28]. The majority of the pa-
tients were males (83.3 %). The median age of patients
was 62 years. By anatomic site, 1 was located in the
upper esophagus, 33 in the middle and 62 in the lower
area. Most of the tumor differentiation was grade II
(63.5 %), 36.5 % was grade III and none was grade 1.
Five tumors had invaded to the submucosa, 24 to the
muscularis propria and 67 to the adventitia. Fifty-three
tumors were associated with nerve or vascular infiltra-
tion and 44 with lymph node metastases.EGFR IHC analysis
Among the 96 ESCC cases analyzed, the EGFR IHC
staining results are evaluated using six scoring systems
(Additional file 1: Table S1). The scoring system 1 and 6
has low, intermediate and high level of EGFR expression,
while 2, 3, 4 and 5 only has low and high level (Table 1).
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EGFR were observed in 8 (8.3 %), 64 (66.7 %), 48 (50 %), 8
(8.3 %), 84 (87.5 %), and 49 (51.0 %) cases, respectively
(Table 1). Within the 6 scoring systems, 17 cases had the
same level of EGFR expression (7 in high level, 10 in low
level, and none in intermediate level) (Additional file 1:
Table S1). Fig. 1a showed the negative control, 1b, 1c, andTable 3 Relationship of status of EGFR in ESCC with the clinicopath
EGFR-IHC result
System 1 System
N L M H P L
Gender
Male 80 42 32 6 0.724 74
Female 16 7 7 2 14
Age
<60 34 24 8 2 0.017 22
>60 62 25 31 6 45
Tumor site
Upper 1 0 1 0 0.181 1
Middle 33 12 17 4 29
Lower 62 37 21 4 58
T-stage
T1 5 2 3 0 0.889 5
T2 24 13 9 2 23
T3 67 34 27 6 60
Vaso invasion
No 77 34 35 8 0.020 69
Yes 19 15 4 0 19
Nerve invasion
No 62 34 24 4 0.497 59
Yes 34 15 15 4 29
LN metastases
No 52 29 22 1 0.046 51
Yes 44 20 17 7 37
Necrosis
No 38 21 16 1 0.258 36
Yes 58 28 23 7 52
Mitoses (/10HPF)
≤20 29 12 15 2 0.645 27
20~50 37 20 13 4 32
≥50 30 17 11 2 29
Tumour differentiation
G2 61 33 26 2 0.061 43
G3 35 16 13 6 24
System 1and System 4, EGFR-IHC scoring system 1 and 4
L, low level of EGFR expression; M, intermediate level; H, high level
FISH positive , EGFR gene amplification or high polysomy1d were low, intermediate and high level of EGFR expres-
sion according to system 1.
There were significant difference among the six IHC
score results (P < 0.001) (Table 1). The scoring system 2
and 3 are highly in agreement with each other (k =
0.87). No comparison could be conducted between 1
and 4.ological parameters
EGFR-FISH result
4 FISH Positive Amplification
H P No Yes P No Yes P
6 0.509 52 28 0.022 74 6 0.861
2 15 1 15 1
12 0.422 22 12 0.422 32 2 0.694
17 45 17 57 5
0 0.607 1 0 0.313 1 0 0.413
4 20 13 29 4
4 46 16 59 3
0 0.499 3 2 0.552 5 0 0.602
1 15 9 23 1
7 49 18 61 6
8 0.142 54 23 0.884 70 7 0.172
0 13 6 19 0
3 0.094 44 18 0.735 59 3 0.212
5 23 11 30 4
1 0.013 39 13 0.227 51 1 0.028
7 28 16 38 6
2 0.378 27 11 0.828 37 1 0.155
6 40 18 52 6
2 0.307 18 11 0.06 27 2 0.768
5 31 6 35 2
1 18 12 27 3
18 0.844 43 18 0.844 57 4 0.715
11 24 11 32 3
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The average gene copy number per cell and the EGFR-to-
chromosome 7 ratio for the major FISH patterns are listed
in Additional file 2: Table S2. EGFR FISH-positive was
seen in 29 (30.2 %) cases. The EGFR genes were amplified
in 7 (7.3 %) cases (6 were clustered-type signals and 1 were
multiple scattered signals) (Figs. 2a and b). High polysomy
(≥4 copies in >40 % of cells) was present in the other 22
(22.9 %) cases, with the averages of EGFR and chromo-
some 7 signals per cell ranging between 3.11 and 5.10 and
the gene-to-chromosome ratio ranging from 0.82 to 1.84
(Fig. 2c). Low polysomy was present in 39 (40.6 %) cases
with the averages of gene and chromosome copies per cell
ranging from 2.43 to 3.27 and the chromosome-to-gene
ratio ranging from 0.92 to 1.14 (Fig. 2d), disomy in 3
(3.1 %) cases, with the averages per cell for the gene and
chromosome 7 copies ranging from 2.02 to 2.17 and the
ratio of gene-to-chromosome from 0.97 to 1.04 (Fig. 2f ),
low trisomy in 19 (19.8 %) cases with the averages per
cell for the gene and chromosome 7 copies ranging
from 1.95 to 2.49 and the ratio of gene-to-chromosome
from 0.74 to 1.12, and high trisomy in 6 (6.3 %) cases
with the averages per cell for the gene and chromosome
7 copies ranging from 2.56 to 2.91 and the ratio ofFig. 3 Association between EGFR overexpression and survival in ESCC. Prot
(a, P = 0.006) and OS (b, P =0.007), with system 2 (c and d) no prognostic vgene-to-chromosome from 0.95 to 1.02 (Fig. 2e). These
cases were categorized as a FISH-negative group.
Correlation between EGFR protein expression and gene
variation
EGFR expression and gene copy number are analyzed
and showed in Table 2. EGFR gene amplification was as-
sociated with EGFR protein overexpression in scoring
system 1, 2, 3, 4, and 6, EGFR-FISH positive only in
scoring system 1, 2 and 4.
On the basis of scoring system 1, 3 and 4, patients
with trisomy and polysomy showed low mean IHC
scores (206 and 197, 6.6 and 6.5, 94.6 and 100 respect-
ively), whereas the mean IHC score increased when
FISH abnormalities became more severe. The mean
score was 348.6, 13.7 and 254.3 for patients with gene
amplification (Additional file 3: Table S3).
Prognostic implication of EGFR protein expression levels
and gene variation
EGFR protein overexpression and gene amplification
were statistically evaluated for correlation with estab-
lished clinicopathological factors (Table 3). EGFR over-
expression according to scoring system 1 and 4 wasein overexpression, on the basis of scoring system 1, had poorer DFS
alue
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node metastasis (P < 0.05, Table 3). No such correction
was observed using other scoring systems. EGFR ampli-
fication was associated with the lymph node metastasis
(P = 0.028), while high polysomy wasn’t associated with
this factor (P = 0.227).
EGFR overexpression and gene amplification were
evaluated for their potential prognostic significance. The
Kaplan-Meier survival curves for patients in the different
scoring systems of EGFR expression or gene numbers
are shown in Figs. 3 and 4. Protein overexpression, on
the basis of scoring system 1, had poorer DFS (P =
0.006) (Fig. 3a) and OS (P = 0.004) (Fig. 3b). However,
other systems had no prognostic value whether in DFS
or in OS (Fig. 3c and d). And gene amplification did not
represent a statistically significant adverse prognosis
until 20 months (Fig. 4). No significant difference in sur-
vival rates with respect to high polysomy was observed.
Discussion
The epithelial growth factor receptor (EGFR) is a 170-
kDa transmembrane glycoprotein and a tyrosine kinase
receptor expressed in various human tissues, especially
in cells of epithelial origin, which plays important roles
in modulating cell proliferation, survival, migration, andFig. 4 Association between EGFR gene variation and survival in ESCC. The
or OS (P = 0.240 or 0.211). However, gene amplification (c and d) did repredifferentiation [29]. EGFR alterations in cancer can be
divided mostly in two categories: mutations in exons
18–21 mainly identified in Asia lung adenocarcinoma
[30, 31], and gene and protein overexpression [32]. It’s
known to us, ESCC predominantly show EGFR gene
copy number alterations and protein overexpression [11,
13, 24, 33], with little EGFR mutation [16, 26, 34]. EGFR
gene variation and protein overexpression might be the
candidate for predictive biomarker in ESCC. There have
been several IHC studies examining EGFR protein ex-
pression in ESCC, the expression rate ranged from 4 %
to 86 % [13, 24, 33]. We found the most important dis-
crepancies might be due to the selected threshold for
positivity, which may induce conflicting results in differ-
ent laboratories and authors. Therefore, we selected six
different scoring systems presented in literature to focus
upon the same ESCC samples with EGFR antibody.
Evaluation of EGFR expression by six scoring systems in
ESCC
Firstly, the overexpression of EGFR were observed in 8
(8.3 %), 64 (66.7), 48 (50 %), 8 (8.3 %), 84 (87.5 %), and 49
(51.0 %) cases according to system 1 to 6, with ranging
from 8.3 % to 87.5 %. These results were in agreement
with our speculation that EGFR expression was obviouslygene amplification (a and b) was not significantly associated with DFS
sent delayed prognostic information (P = 0.037 and 0.031)
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ation of EGFR expression with clinical features and prog-
nosis were evaluated by scoring system 1 to 6, 1 and 4
related to lymph node metastasis, however, only 1 showed
a statistically significant prognosis with DFS (0.006) and
OS (0.007). Therefore, scoring system 1 for EGFR expres-
sion seems to be more valuable for predicting tumor ag-
gressiveness and prognosis.
Evaluation of EGFR gene variation in ESCC
Firstly, EGFR gene status disclosed by our FISH included
disomy, low trisomy, high trisomy, low polysomy, high
polysomy and gene amplification, which was consistent
with previous reports [24]. Secondly, EGFR gene amplifi-
cation was associated with EGFR expression evaluated
by scoring system 1, 2, 3, 4, 6 except 5, whereas EGFR-
FISH positive was only associated with scoring system 1,
2 and 4. Thirdly, EGFR-FISH positive had no relation-
ship with clinical features and prognosis; however, EGFR
amplification was associated with lymph node metasta-
sis, and patients with EGFR amplification had poorer
prognosis whether in DFS or OS after 20 months sur-
vival. Therefore, EGFR amplification, not EGFR-FISH
positive or high polysomy, seems to be a suitable cut off
value in clinical practice.
Conclusion
This study firstly compared six scoring system evalu-
ation for EGFR IHC overexpression used in ESCC, and
found scoring system 1 might be suitable to be adopted
in clinical practice since the value in predicting patients’
survival. EGFR gene amplification was associated with
protein overexpression in ESCC, and indicated poorer
prognosis after 20 months survival.
Additional files
Additional file 1: Table S1. EGFR immunohistochemical staining results
evaluated using six scoring systems.
Additional file 2: Table S2. EGFR-FISH results of all cases.
Additional file 3: Table S3. EGFR IHC scores and gene variation.
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